Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the randomized Phase II PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab
European Journal of Cancer · 2024
DOI: 10.1016/j.ejca.2024.115050 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2024. Verfasst von Martin Reck und 7 weiteren Autor:innen. Beteiligte Einrichtung: LungenClinic, Airway Research Center North, Center for Lung Research, Grosshansdorf, Germany. Electronic address: M.Reck@lungenclinic.de. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Patient Reported Outcome Measures. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: PERLA (NCT04581824) compared efficacy and safety of dostarlimab (DCT) or pembrolizumab (PCT) plus chemotherapy as first-line treatment for metastatic non-small cell lung cancer. Here, we report patient-reported outcomes (PROs; exploratory analysis) from PERLA. METHODS: Patients were randomized 1:1 to receive DCT or PCT every 3 weeks (Q3W) for ≤ 35 cycles [C]. PROs (EORTC QLQ-C30 and QLQ-LC13, PRO-CTCAE, FACT-GP5) were collected at baseline, Q3W until C4, Q9W until C16, Q12W until end of treatment and at 30-day safety follow-up. Change from baseline and time to deterioration (TTD) in QLQ-C30 and QLQ-LC13 were analyzed using longitudinal mixed models and Kaplan-Meier estimators, respectively. RESULTS: The PRO (DCT/PCT) datasets included 102/99 patients for QLQ-C30, 96/90 for QLQ-LC13, 96/88 for PRO-CTCAE, and 95/87 for FACT-GP5. Completion rates were > 80 % to C4, then decreased in both arms. For QLQ-C30 and QLQ-LC13, most patients reported stable/improved responses at C13 (∼ 9 months on treatment), with similar responses between arms except more patients reported improvements in dyspnea (QLQ-C30: 36.4 % vs 13.0 %; QLQ-LC13: 40.6 % vs 25.0 %) and chest pain (QLQ-LC13: 34.4 % vs 10.0 %) with DCT vs PCT. TTD per QLQ-C30 and QLQ-LC13 were similar between arms, although TTD in dyspnea was longer with DCT vs PCT (QLQ-LC13: 4.24 vs 1.54 months; p = 0.0168). Most patients in both arms reported that adverse events occurred occasionally/rarely/never with moderate/mild severity. Overall, patients reported little/no bother from treatment side effects. CONCLUSIONS: DCT maintained health-related quality of life similarly to PCT and was well tolerated, supporting the PERLA primary results and dostarlimab use in future regimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- LungenClinic, Airway Research Center North, Center for Lung Research, Grosshansdorf, Germany. Electronic address: M.Reck@lungenclinic.de.
- Servicio de Oncología Médica, Hospital Universitario de Jaén, Jaén, Spain.
- European Institute of Oncology IRCCS, Milan, Italy.
- GSK, Collegeville, PA, USA.
- GSK, Baar, Switzerland.
Zitieren
APA
Reck, M., Granados, A. L. O., de Marinis, F., Meyers, O., Shen, Q., Cho, L., Stjepanovic, N., & Boklage, S. (2024). Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the randomized Phase II PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.115050
Vancouver
Reck M, Granados ALO, de Marinis F, Meyers O, Shen Q, Cho L, et al. Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the randomized Phase II PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.115050
BibTeX
@article{Reck2024,
author = {Reck, Martin and Granados, Ana Laura Ortega and de Marinis, Filippo and Meyers, Oren and Shen, Qin and Cho, Lillian and Stjepanovic, Neda and Boklage, Susan},
title = {Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the randomized Phase II PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab},
journal = {European Journal of Cancer},
year = {2024},
doi = {10.1016/j.ejca.2024.115050}
}
EUVIMED